Merck and Moderna Stocks Rally on Promising Melanoma Vaccine Results

Stocks for pharmaceutical giants Merck and Moderna surged on Wednesday morning after a promising study revealed that their collaborative mRNA vaccine had shown significant success in treating melanoma.

A late-stage trial demonstrated that the vaccine helped reduce the recurrence of skin cancer, a breakthrough that has sent shares soaring.

The news comes as the pharmaceutical industry continues to push the boundaries of medical research and innovation.